US FDA has issued new guidelines to providers because some patients experienced strokes or died after being treated for unruptured brain aneurysms with some neurovascular stents.

The International Stroke Conference in Los Angeles featured new data that will support an FDA submission for J&J/Cerenovous' EmboTrap revascularization device. The findings showed a high rate of "first-pass" effectiveness and EmboTrap was successful in creating final substantial reperfusion in 90% of the treated patients.

Innovation is driving double-digit growth in the neurointerventional device market as an increasing number of medical device manufacturers develop newer, more effective devices for treating acute ischemic stroke. As new, stent-like retrieval systems and other next-generation neurothrombectomy devices hit the US market in the next few years, competition in this sector will also heat up as manufacturers try to differentiate their devices and jockey for a piece of the market, which is projected to reach almost $70 million by 2015.

Innovation is driving double-digit growth in the neurointerventional device market as an increasing number of medical device manufacturers develop newer, more effective devices for treating acute ischemic stroke. As new, stent-like retrieval systems and other next-generation neurothrombectomy devices hit the US market in the next few years, competition in this sector will also heat up as manufacturers try to differentiate their devices and jockey for a piece of the market, which is projected to reach almost $70 million by 2015.